home / stock / gnbt / gnbt news

GNBT News and Press, Generex Biotechnology From 02/27/20

Stock Information
Company Name: Generex Biotechnology
Stock Symbol: GNBT
Market: OTC
Website: generex.com
Menu
GNBT GNBT Quote GNBT Short GNBT News GNBT Articles GNBT Message Board
Get GNBT Alerts

News, Short Squeeze, Breakout and More Instantly...
GNBT - Generex Provides Coronavirus Update: Generex Receives Contract from Chinese Partners to Develop a COVID-19 Vaccine Using Ii-Key Peptide Vaccines

-- Terms approved to proceed with collaborative effort with international consortium MIRAMAR, Fla., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation ( www.generex.com ) (OTCQB:GNBT) ( http://www.otcmarkets.com/stock/GNBT/quote ) today announced that the company has...
GNBT - Generex Issues Clarification on Stock Dividends

Dividends officially paid on Monday, February 24, 2020 °  Ex-Dividend Date does not apply to NuGenerex Immuno-Oncology shares MIRAMAR, Fla., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation ( www.generex.com ) (OTCQB:GNBT) (“Generex”) today cla...

GNBT - Generex Congratulates their Shareholders as FINRA has Officially Posted the Approval of the Generex Corporate Action and Payment of the Generex and NuGenerex Immuno-Oncology Stock Dividends on Monday, February 24, 2020

Dividends officially to be paid on Monday, February 24, 2020 •  Shareholders to receive 2 to 5 stock dividend of Generex Biotechnology shares plus an additional 2 to 5 stock dividend of NuGenerex Immuno-Oncology shares Ex-Date will be February 25, 2020 MIRAMAR, Fla., Feb. 2...

GNBT - Generex Biotechnology Announces Investor Conference Dial-In Details Addressing the Coronavirus Pandemic with Ii-Key Peptide Vaccines and Corporate Update Thursday February 13, 2020 at 11:00 AM EST

MIRAMAR, Fla., Feb. 12, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today announced call-in details for the upcoming investor conference call on Thursday February 13th 2020 at 11:00am AM Eastern time. The access information for the investor c...
GNBT - Generex Biotechnology Announces Corporate Update and Investor Conference Call: Addressing the Coronavirus Pandemic with Ii-Key Peptide Vaccines - Thursday February 13, 2020 at 11:00 AM EST

MIRAMAR, Fla., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation ( www.generex.com ) (OTCQB:GNBT) today announced that Joe Moscato, President & Chief Executive Officer and the team from NuGenerex Immuno-Oncology will hold an investor conference call on Thursday Febr...

GNBT - Generex Declares NEW Dividend RECORD DATE: Monday, February 17, 2020

PAY DATE: Monday, February 24, 2020 EX DATE: Tuesday, February 25, 2020 MIRAMAR, Fla., Feb. 07, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation ( www.generex.com ) (OTCQB:GNBT) (“Generex”) is pleased to announce the successful completion of the FINRA review proce...

GNBT - Generex Provides Stock Dividend Updates and Guidance

Awaiting completion of FINRA approval process Dividends remain the same Shareholders to receive 2 to 5 stock dividend of Generex Biotechnology shares plus an additional 2 to 5 stock dividend of NuGenerex Immuno-Oncology shares MIRAMAR, Fla., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Gener...
GNBT - Generex Biotechnology Discusses Coronavirus Solutions with The Stock Day Podcast

Phoenix, Arizona--(Newsfile Corp. - February 6, 2020) - The Stock Day Podcast welcomed Generex Biotechnology (OTCQB: GNBT) ("the Company"), an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapie...

GNBT - Generex Biotechnology Subsidiaries NuGenerex Immuno-Oncology and NuGenerex Diagnostics Working to Address the Coronavirus Pandemic and Emerging Risk of Avian Flu Using Ii-Key Peptide Vaccines

NuGenerex Immuno-Oncology’s Ii-Key technology is clinically proven to activate the immune system against numerous viruses including H5N1 avian influenza virus  Ii-Key peptide vaccines offer real potential for a cost effective, rapid response vaccine that can provide immunit...

GNBT - Generex Biotechnology Appoints Independent Director Carol Nacy, PhD to the NuGenerex Immuno-Oncology Board of Directors

MIRAMAR, Fla., Feb. 05, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation ( www.generex.com ) (OTCQB:GNBT) ( http://www.otcmarkets.com/stock/GNBT/quote ) is proud to announce the appointment of Dr. Carol Nacy, PhD to the NuGenerex Immuno-Oncology (NGIO) Board of Directors. Dr. Na...
Previous 10 Next 10